The latest biotech news

News and Trends 26 Apr 2023

aVaxziPen’s needle-free vaccine yields positive data across multiple diseases

aVaxziPen, a biotech company developing a novel needle-free vaccine delivery platform, presented data at the World Vaccine Congress (WVC) in Washington, U.S., recently. The company presented a poster entitled, “Needle-free, injectable solid dose vaccine delivery generates equivalent immune response with different antigens and animal models.” The company said immunogenicity data from four in vivo models […]

April 26, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 26 Apr 2023

Global partners announce The Big Catch-up vaccination effort

WHO, UNICEF, Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation, along with Immunization Agenda 2030 and many other global and national health partners, are joining forces to call for “The Big Catch-up,” a targeted global effort to boost vaccination among children following declines driven by the COVID-19 pandemic. Gavi, the Vaccine Alliance, […]

April 26, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 26 Apr 2023

20Med Therapeutics and Touchlight collaborating on novel vaccine delivery platform

20Med Therapeutics, a company working on non-viral delivery and development of gene therapies and vaccines, and Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, have announced that both parties will collaborate on establishing a novel vaccination platform that combines Touchlight’s rapid enzymatic doggybone DNA platform with 20Med Therapeutics’ bioresponsive […]

April 26, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 25 Apr 2023

Gene therapy and chemotherapy could be new osteosarcoma treatment option

New research has identified a potential therapeutic target and developed a unique delivery system to treat osteosarcoma, a bone cancer that primarily affects children and adolescents. The standard-of-care treatment plan for osteosarcoma today is no different to when first introduced almost 50 years ago. However, nearly one third of patients’ relapse and need new interventions. […]

April 25, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 24 Apr 2023

LifeArc launches £40M funding call to create Translational Rare Disease Centres

LifeArc is inviting applications from academic institutions for its latest £40 million ($49.8 million) initiative to fund four or five new Translational Rare Disease Centres in the U.K., along with a separate co-ordinating hub. LifeArc, which is a self-funded, non-profit medical research charity, specializes in early-stage translation – the advancement of scientific discoveries towards patient […]

April 24, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 24 Apr 2023

RNA-based nanodrugs cause cancer cells to collapse – 80% survival rate for ovarian cancer in lab models

Researchers from Tel Aviv University in Israel have revealed details of a new approach to the treatment of ovarian cancer using RNA-based nanodrugs – demonstrating an 80% survival rate in lab models.In a study at Tel Aviv University, the protein CKAP5 (cytoskeleton-associated protein) was used for the first time as a therapeutic target for RNA-based […]

April 24, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 24 Apr 2023

Life Biosciences gene therapy data shows visual function restored in primates

Life Biosciences (Life Bio) has announced preclinical data in nonhuman primates (NHP) for its novel gene therapy candidate, which uses a partial epigenetic reprogramming approach to restore visual function. The approach has been shown to reverse aging, improve vision, and extend lifespan in mice, but whether epigenetic reprogramming would work in primates was not known. […]

April 24, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 21 Apr 2023

New discovery “an area of cancer research with tremendous promise for breakthroughs”

A research team led by Gary Ying Wai Chan from the School of Biological Sciences at The University of Hong Kong (HKU), has revealed the function of a unique enzyme, ANKLE1. ANKLE1 acts on chromatin bridges trapped in the midzone of dividing cells. By cutting these bridges, ANKLE1 prevents damage to the genetic material and […]

April 21, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 21 Apr 2023

RetinAI and Boehringer Ingelheim to use AI to develop treatment for geographic atrophy

RetinAI Medical AG, which creates clinical and imaging data management software and advanced analytics using artificial intelligence (AI) for ophthalmology, is partnering with Boehringer Ingelheim. The companies aim to improve patient outcomes in geographic atrophy (GA) by combining RetinAI’s Discovery platform and AI tools with Boehringer Ingelheim’s research in retinal diseases. GA is a progressive, […]

April 21, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 21 Apr 2023

Orphalan announces U.S. launch of drug to treat Wilson disease

Orphalan SA, an international orphan drug development and commercialization company, has announced the commercial launch in the U.S. for Cuvrior. Cuvrior is a new trientine tetrahydrochloride (TETA-4HCl). It is now available for the treatment of adult patients with stable Wilson disease who are de-coppered and tolerant to D-penicillamine. Cuvrior was approved by the United States […]

April 21, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 21 Apr 2023

Can artificial intelligence predict future pandemics?

Before the first cases of COVID-19 became known, an algorithm based on artificial intelligence developed by a company in Canada had already detected a new virus spreading across the Chinese city of Wuhan. This demonstration of the potential of new technologies applied to predicting future epidemics led a group of researchers at the Universitat Oberta […]

April 21, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 20 Apr 2023

FDA approves Genentech’s lymphoma drug

Genentech, a member of the Roche Group, has announced the U.S. Food and Drug Administration (FDA) has approved Polivy (polatuzumab vedotin-piiq) in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP). The approval covers the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell […]

April 20, 2023 - 4 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

aVaxziPen’s needle-free vaccine yields positive data across multiple diseases

Global partners announce The Big Catch-up vaccination effort

20Med Therapeutics and Touchlight collaborating on novel vaccine delivery platform

Gene therapy and chemotherapy could be new osteosarcoma treatment option

LifeArc launches £40M funding call to create Translational Rare Disease Centres

RNA-based nanodrugs cause cancer cells to collapse – 80% survival rate for ovarian cancer in lab models

Life Biosciences gene therapy data shows visual function restored in primates

New discovery “an area of cancer research with tremendous promise for breakthroughs”

RetinAI and Boehringer Ingelheim to use AI to develop treatment for geographic atrophy

Orphalan announces U.S. launch of drug to treat Wilson disease

Can artificial intelligence predict future pandemics?

FDA approves Genentech’s lymphoma drug

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!